Endocrine Side Effects of Broad-acting Kinase Inhibitors

Overview

Journal Endocr Relat Cancer

Specialties Endocrinology
Oncology

Date 2010 Jul 7

PMID 20603395

Citations 27

Authors

Maya B Lodish

Constantine A Stratakis

Affiliations

Soon will be listed here.

Abstract

Targeted therapy in oncology consists of drugs that specifically interfere with abnormal signaling pathways that are dysregulated in cancer cells. Tyrosine kinase inhibitors (TKIs) take advantage of unique oncogenes that are activated in certain types of cancer, and also target common mechanisms of growth, invasion, metastasis, and angiogenesis. However, many kinase inhibitors for cancer therapy are somewhat nonselective, and most have additional mechanisms of action at the cellular level, which are not completely understood. The use of these agents has increased our knowledge of important side effects, of which the practicing clinician must be aware. Recently, proposed endocrine-related side effects of these agents include alterations in thyroid function, bone metabolism, linear growth, gonadal function, fetal development, and glucose metabolism, and adrenal function. This review summarizes the most recent data on the endocrine side effects of TKIs.

Citing Articles

Bone Mineral Density, C-Terminal Telopeptide of Type I Collagen, and Osteocalcin as Monitoring Parameters of Bone Remodeling in CML Patients Undergoing Imatinib Therapy: A Basic Science and Clinical Review.

Indarwulan N, Savitri M, Ashariati A, Bintoro S, Noor Diansyah M, Ayu Amrita P Diseases. 2024; 12(11).

PMID: 39589949 PMC: 11592756. DOI: 10.3390/diseases12110275.

Gilteritinib-Induced Hypopituitarism: A Case Report.

Hori Y, Okada Y, Sonoda S, Torimoto K, Tanaka Y Cureus. 2024; 16(9):e70401.

PMID: 39473682 PMC: 11518918. DOI: 10.7759/cureus.70401.

Therapeutic advances of targeting receptor tyrosine kinases in cancer.

Tomuleasa C, Tigu A, Munteanu R, Moldovan C, Kegyes D, Onaciu A Signal Transduct Target Ther. 2024; 9(1):201.

PMID: 39138146 PMC: 11323831. DOI: 10.1038/s41392-024-01899-w.

Tyrosine kinase inhibitor-induced hypothyroidism: mechanism and clinical implications.

Wang Z, Wang H, Bu C, Meng B, Mu Y, Gao S Eur J Clin Pharmacol. 2024; 80(6):827-838.

PMID: 38483545 DOI: 10.1007/s00228-024-03626-4.

Severe Hyperglycemia Due to Protein Kinase Inhibitor Therapy in a Patient With Poorly Controlled Diabetes Mellitus.

Sontag I, Bergmann L, Adamek H JCEM Case Rep. 2024; 2(1):luad172.

PMID: 38188906 PMC: 10768878. DOI: 10.1210/jcemcr/luad172.

References

Meric-Bernstam F, Gonzalez-Angulo A . Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 2009; 27(13):2278-87. PMC: 2738634. DOI: 10.1200/JCO.2008.20.0766. View

Badros A, Siegel E, Bodenner D, Zangari M, Zeldis J, Barlogie B . Hypothyroidism in patients with multiple myeloma following treatment with thalidomide. Am J Med. 2002; 112(5):412-3. DOI: 10.1016/s0002-9343(01)01137-8. View

Caocci G, Atzeni S, Orru N, Azzena L, Martorana L, Littera R . Gynecomastia in a male after dasatinib treatment for chronic myeloid leukemia. Leukemia. 2008; 22(11):2127-8. DOI: 10.1038/leu.2008.106. View

Lodish M, Stratakis C . RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer. Expert Rev Anticancer Ther. 2008; 8(4):625-32. PMC: 2670186. DOI: 10.1586/14737140.8.4.625. View

Wolter P, Stefan C, Decallonne B, Dumez H, Bex M, Carmeliet P . The clinical implications of sunitinib-induced hypothyroidism: a prospective evaluation. Br J Cancer. 2008; 99(3):448-54. PMC: 2527784. DOI: 10.1038/sj.bjc.6604497. View

Sebolt-Leopold J . Advances in the development of cancer therapeutics directed against the RAS-mitogen-activated protein kinase pathway. Clin Cancer Res. 2008; 14(12):3651-6. DOI: 10.1158/1078-0432.CCR-08-0333. View

Hamberg P, de Jong F, Boonstra J, van Doorn J, Verweij J, Sleijfer S . Non-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinib. J Clin Oncol. 2006; 24(18):e30-1. DOI: 10.1200/JCO.2006.06.5318. View

Fabian M, Biggs 3rd W, Treiber D, Atteridge C, Azimioara M, Benedetti M . A small molecule-kinase interaction map for clinical kinase inhibitors. Nat Biotechnol. 2005; 23(3):329-36. DOI: 10.1038/nbt1068. View

Hagerkvist R, Sandler S, Mokhtari D, Welsh N . Amelioration of diabetes by imatinib mesylate (Gleevec): role of beta-cell NF-kappaB activation and anti-apoptotic preconditioning. FASEB J. 2006; 21(2):618-28. DOI: 10.1096/fj.06-6910com. View

10.

Daub H . Kinase inhibitors: narrowing down the real targets. Nat Chem Biol. 2010; 6(4):249-50. DOI: 10.1038/nchembio.336. View

11.

Mannavola D, Coco P, Vannucchi G, Bertuelli R, Carletto M, Casali P . A novel tyrosine-kinase selective inhibitor, sunitinib, induces transient hypothyroidism by blocking iodine uptake. J Clin Endocrinol Metab. 2007; 92(9):3531-4. DOI: 10.1210/jc.2007-0586. View

12.

Dora J, Leie M, Netto B, Fogliatto L, Silla L, Torres F . Lack of imatinib-induced thyroid dysfunction in a cohort of non-thyroidectomized patients. Eur J Endocrinol. 2008; 158(5):771-2. DOI: 10.1530/EJE-08-0006. View

13.

Wells Jr S, Gosnell J, Gagel R, Moley J, Pfister D, Sosa J . Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol. 2010; 28(5):767-72. PMC: 2834392. DOI: 10.1200/JCO.2009.23.6604. View

14.

Sherman S . Advances in chemotherapy of differentiated epithelial and medullary thyroid cancers. J Clin Endocrinol Metab. 2009; 94(5):1493-9. DOI: 10.1210/jc.2008-0923. View

15.

Gavi S, Shumay E, Wang H, Malbon C . G-protein-coupled receptors and tyrosine kinases: crossroads in cell signaling and regulation. Trends Endocrinol Metab. 2006; 17(2):48-54. DOI: 10.1016/j.tem.2006.01.006. View

16.

Rock E, Goodman V, Jiang J, Mahjoob K, Verbois S, Morse D . Food and Drug Administration drug approval summary: Sunitinib malate for the treatment of gastrointestinal stromal tumor and advanced renal cell carcinoma. Oncologist. 2007; 12(1):107-13. DOI: 10.1634/theoncologist.12-1-107. View

17.

Jonsson S, Olsson B, Ohlsson C, Lorentzon M, Mellstrom D, Wadenvik H . Increased cortical bone mineralization in imatinib treated patients with chronic myelogenous leukemia. Haematologica. 2008; 93(7):1101-3. DOI: 10.3324/haematol.12373. View

18.

Weijl N, Van der Harst D, Brand A, Kooy Y, Van Luxemburg S, Schroder J . Hypothyroidism during immunotherapy with interleukin-2 is associated with antithyroid antibodies and response to treatment. J Clin Oncol. 1993; 11(7):1376-83. DOI: 10.1200/JCO.1993.11.7.1376. View

19.

Wells Jr S, Santoro M . Targeting the RET pathway in thyroid cancer. Clin Cancer Res. 2009; 15(23):7119-23. DOI: 10.1158/1078-0432.CCR-08-2742. View

20.

Billemont B, Medioni J, Taillade L, Helley D, Meric J, Rixe O . Blood glucose levels in patients with metastatic renal cell carcinoma treated with sunitinib. Br J Cancer. 2008; 99(9):1380-2. PMC: 2579676. DOI: 10.1038/sj.bjc.6604709. View